# Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

> **NCT00513240** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 62 (actual)

## Conditions studied

- Congenital Heart Disease
- Hypoplastic Left Heart Syndrome
- Transposition of the Great Arteries
- Aortic Arch Hypoplasia or Interruption

## Interventions

- **DRUG:** Erythropoetin
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT00513240
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2012-09
- **Final completion:** 2015-09
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513240, "Erythropoetin Neuroprotection for Neonatal Cardiac Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00513240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*